NEW YORK, Oct. 4 – Bioinformatics company Genomica said Thursday it was eliminating 100 jobs, or 67 percent of its workforce, after determining that the company could not realize its original goals of delivering novel software tools to the genomics market.

"Our initial target market for third-party enterprise software is not developing fast enough to build stockholder value within a reasonable timeframe,” Genomica CEO Teresa Ayers said in a statement.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.